AI-generated summary
The authors describe four adults with relapsed or refractory multiple myeloma who received photobiomodulation alongside talquetamab, reporting on the feasibility and tolerability of the treatment. All four developed dysgeusia and xerostomia, and the authors report that photobiomodulation was well tolerated with no related adverse events. Because the series is small and uncontrolled, the authors state that no conclusion about efficacy can be drawn.
- Participants
- 4
- Who or what was studied
- Four adults with relapsed/refractory multiple myeloma receiving talquetamab
- Wavelengths
- 660, 808 nm
- Limits stated in the abstract
- The sample is small and uncontrolled, supportive care was given concurrently, and dysgeusia and xerostomia were not measured with objective, validated tests.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background
Talquetamab, a GPRC5D-targeting bispecific antibody, produces high response rates in relapsed/refractory multiple myeloma (RRMM) but is frequently associated with oral adverse effects, most commonly dysgeusia and xerostomia, which can impair nutrition and quality of life. No evidence-based supportive-care intervention has been established for these effects.
Methods
We describe four adults with RRMM who received photobiomodulation (PBM) concomitantly with talquetamab, using a dual-wavelength (660/808 nm) protocol individualized to symptom evolution and patient availability. Dysgeusia and xerostomia were assessed prospectively at each session through structured clinical interview and oral examination, with severity graded for each patient; no formal psychophysical gustatory testing or sialometry was performed. This descriptive, uncontrolled case series was designed to report the feasibility and tolerability of PBM rather than its efficacy.
Results
All four patients developed dysgeusia during talquetamab treatment. Two had grade 1, intermittent hypogeusia; two had grade 2 dysgeusia with complete taste loss (ageusia). No patient developed oral mucositis or clinically significant oral pain. All four patients reported xerostomia, with reduced salivary film and whitish, viscous saliva on examination; salivary flow was not measured quantitatively. All patients also received xylitol-based mouthwash and saliva substitutes from the start of talquetamab as concomitant standard supportive care. PBM was well tolerated, with no PBM-related adverse events, and no patient discontinued talquetamab because of oral toxicity.
Conclusions
This series demonstrates the feasibility and tolerability of PBM delivered alongside talquetamab in four patients. Given the small, uncontrolled sample and concurrent supportive interventions, no conclusion can be drawn regarding the efficacy of PBM for talquetamab-associated dysgeusia or xerostomia. Controlled studies with objective, validated outcome measures are needed.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 808 nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, GRADE, Oral mucositis, Wavelength. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.